These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 16614241)

  • 21. Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent.
    Kim SH; Kim D; Kim DW; Goh HG; Jang SE; Lee J; Kim WS; Kweon IY; Park SH
    Hematol Oncol; 2009 Dec; 27(4):190-7. PubMed ID: 19274615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL.
    Breccia M; Alimena G
    Curr Drug Targets; 2009 Jun; 10(6):530-6. PubMed ID: 19519355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
    Jabbour E; Jones D; Kantarjian HM; O'Brien S; Tam C; Koller C; Burger JA; Borthakur G; Wierda WG; Cortes J
    Blood; 2009 Sep; 114(10):2037-43. PubMed ID: 19567878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
    Ernst T; Gruber FX; Pelz-Ackermann O; Maier J; Pfirrmann M; Müller MC; Mikkola I; Porkka K; Niederwieser D; Hochhaus A; Lange T
    Haematologica; 2009 Sep; 94(9):1227-35. PubMed ID: 19608684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
    Jabbour E; Branford S; Saglio G; Jones D; Cortes JE; Kantarjian HM
    Cancer; 2011 May; 117(9):1800-11. PubMed ID: 21509757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
    Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overcoming resistance in chronic myelogenous leukemia.
    Cooper S; Giles FJ; Savona MR
    Leuk Lymphoma; 2009 Nov; 50(11):1785-93. PubMed ID: 19883308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
    Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
    Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
    Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
    Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients.
    Qin Y; Chen S; Jiang B; Jiang Q; Jiang H; Li J; Li L; Lai Y; Liu Y; Huang X
    Ann Hematol; 2011 Jan; 90(1):47-52. PubMed ID: 20697894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia.
    Mughal TI; Goldman JM
    Clin Lymphoma Myeloma; 2007 Mar; 7 Suppl 2():S81-4. PubMed ID: 17382017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
    Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.
    Maekawa T; Ashihara E; Kimura S
    Int J Clin Oncol; 2007 Oct; 12(5):327-40. PubMed ID: 17929114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
    O'Hare T; Walters DK; Stoffregen EP; Jia T; Manley PW; Mestan J; Cowan-Jacob SW; Lee FY; Heinrich MC; Deininger MW; Druker BJ
    Cancer Res; 2005 Jun; 65(11):4500-5. PubMed ID: 15930265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations.
    Bradeen HA; Eide CA; O'Hare T; Johnson KJ; Willis SG; Lee FY; Druker BJ; Deininger MW
    Blood; 2006 Oct; 108(7):2332-8. PubMed ID: 16772610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?
    Gruber FX; Lundán T; Goll R; Silye A; Mikkola I; Rekvig OP; Knuutila S; Remes K; Gedde-Dahl T; Porkka K; Hjorth-Hansen H
    Med Oncol; 2012 Mar; 29(1):219-26. PubMed ID: 21221851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
    Tanaka R; Kimura S
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure.
    Kwan TK; Ma ES; Chan YY; Wan TS; Liu HS; Sim JP; Yeung YM; Lie AK; Yip SF
    Hong Kong Med J; 2009 Oct; 15(5):365-73. PubMed ID: 19801694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful treatment with nilotinib after imatinib failure in a CML patient with a four-way Ph chromosome translocation and point mutations in BCR/ABL gene.
    Okada M; Satake A; Kaida K; Taniguchi K; Yoshihara S; Ikegame K; Tamaki H; Soma T; Fujimori Y; Ogawa H
    Int J Hematol; 2011 Feb; 93(2):243-246. PubMed ID: 21279819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
    Shah NP; Skaggs BJ; Branford S; Hughes TP; Nicoll JM; Paquette RL; Sawyers CL
    J Clin Invest; 2007 Sep; 117(9):2562-9. PubMed ID: 17710227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.